Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -63.29% | -23.23% | -4.44% | 16.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -63.29% | -23.23% | -4.44% | 16.74% |
| Cost of Revenue | 26.98% | 23.67% | 36.86% | 91.05% | 180.45% |
| Gross Profit | -37.65% | -30.46% | -41.36% | -102.97% | -217.91% |
| SG&A Expenses | 33.24% | 22.28% | 32.81% | 37.89% | 60.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.23% | 23.39% | 36.04% | 77.72% | 143.81% |
| Operating Income | -36.71% | -28.73% | -39.53% | -85.17% | -162.70% |
| Income Before Tax | -19.75% | -9.50% | 27.50% | 27.05% | 19.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.75% | -9.50% | 27.50% | 27.05% | 19.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.75% | -9.50% | 27.50% | 27.05% | 19.12% |
| EBIT | -36.71% | -28.73% | -39.53% | -85.17% | -162.70% |
| EBITDA | -36.76% | -28.81% | -39.34% | -85.22% | -163.31% |
| EPS Basic | 18.54% | 25.81% | 53.37% | 51.28% | 45.30% |
| Normalized Basic EPS | 5.11% | 10.85% | 1.81% | -41.05% | -72.46% |
| EPS Diluted | 18.64% | 25.89% | 53.40% | 51.22% | 45.24% |
| Normalized Diluted EPS | 5.11% | 10.85% | 1.81% | -41.05% | -72.46% |
| Average Basic Shares Outstanding | 41.40% | 45.98% | 48.94% | 47.90% | 73.88% |
| Average Diluted Shares Outstanding | 41.40% | 45.98% | 48.94% | 47.90% | 73.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |